menu
    • menu
    [{"orgOrder":0,"company":"Rayner","sponsor":"Omeros","pharmaFlowCategory":"D","amount":"$1,326 million","upfrontCash":"$126.0 million","newsHeadline":"Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"February 2023","year":"2023","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Rayner","amount2":1.3300000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.3300000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Rayner \/ Rayner","highestDevelopmentStatusID":"12","companyTruncated":"Rayner \/ Rayner"},{"orgOrder":0,"company":"Rayner","sponsor":"Omeros","pharmaFlowCategory":"D","amount":"$1,325 million","upfrontCash":"$125.0 million","newsHeadline":"Omeros Announces Agreement to Sell OMIDRIA\u00ae Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Rayner","amount2":1.3300000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.3300000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Rayner \/ Rayner","highestDevelopmentStatusID":"12","companyTruncated":"Rayner \/ Rayner"},{"orgOrder":0,"company":"Rayner","sponsor":"Omeros","pharmaFlowCategory":"D","amount":"$1,326 million","upfrontCash":"$126.0 million","newsHeadline":"Omeros Completes Sale of OMIDRIA\u00ae Franchise to Rayner Surgical","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"December 2021","year":"2021","type":"Divestment","leadProduct":"Phenylephrine Hydrochloride","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Rayner","amount2":1.3300000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.3300000000000001,"dosageForm":"Solution\/Drops","sponsorNew":"Rayner \/ Rayner","highestDevelopmentStatusID":"12","companyTruncated":"Rayner \/ Rayner"}]

    Find Clinical Drug Pipeline Developments & Deals by Rayner

    Menu

    Rayner

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rayner

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed

                            Rayner

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Omeros

                            Deal Size : $1,326 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical

                            Details : Under the terms of the Agreement, the royalty rate applicable to U.S. net sales of OMIDRIA (phenylephrine) decreased from 50 percent to 30 percent of U.S. net sales following achievement of the Milestone Event.

                            Brand Name : Omidria

                            Molecule Type : Small molecule

                            Upfront Cash : $126.0 million

                            February 06, 2023

                            Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Omeros

                            Deal Size : $1,326 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rayner

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed

                            Rayner

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Omeros

                            Deal Size : $1,326 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical

                            Details : As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.

                            Brand Name : Omidria

                            Molecule Type : Small molecule

                            Upfront Cash : $126.0 million

                            December 23, 2021

                            Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Omeros

                            Deal Size : $1,326 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rayner

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed

                            Rayner

                            United Kingdom arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Recipient : Omeros

                            Deal Size : $1,325 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of...

                            Details : As part of the agreement, Rayner will acquire the OMIDRIA (phenylephrine) commercial organization, including the OMIDRIA sales force. In addition, Rayner plans to expand the sales force in both the U.S. and ex-U.S.

                            Brand Name : Omidria

                            Molecule Type : Small molecule

                            Upfront Cash : $125.0 million

                            December 02, 2021

                            Lead Product(s) : Phenylephrine Hydrochloride,Ketorolac Trometamol

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Recipient : Omeros

                            Deal Size : $1,325 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth